// App-Quantinova.ai

2105 : c-Met hyperactivation is an universal resistance mechanism to both first and third generation EGFR inhibitors

Researchers

Presenter

  • Puyu Shi

Principal Investigators

  • You-Take Oh

  • Guojing Zhang

  • Weilong Yao

  • Ping Yue

  • Rajani Kanteti

  • Jacob Riehm

  • Ravi Salgia

  • Taofeek Owonikoko

  • Suresh S. Ramalingam

  • Mingwei Chen

  • Shi-Yong Sun

Medical Centers

  • Emory University, Winship Cancer Institute, Atlanta, GA

  • Department of Medicine, Section of Hematology and Oncology, The University of Chicago, Chicago, IL

  • Department of Respiration, First Affiliated Hospital of Medical College of Xian Jiaotong University,, Xian, Shaanxi, China.

Locations

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Non Small Cell Lung cancer

Biomarkers

  • Threonine at amino acid position 790

Drug/Treatment

  • Erlotinib hydrochloride

  • L-Tyrosine

  • Tagrisso

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved